SeluDex

SeluDex Logo

International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia

Trial Overview and Summary


 Key Details

Chief Investigator:

Dr Tobias Menne

Sponsor: 

University of Birmingham

Funder:

Cancer Research UK and AstraZeneca

Disease Site: 

Acute Lymphoblastic Leukaemia (ALL)

Trial Type:

Clinical Trial of an Investigational Medicinal Product

Status:

Open

UKCRN Study ID:

33990

Open to New Sites? 

Yes

Recruitment Start Date:

17-Apr-2018

Anticipated Recruitment End Date: 

17-Apr-2020

CRCTU Trial Management Team: 

Early Drug Development Team

Trial Email Adress:

seludex@trials.bham.ac.uk

Trial Summary

This trial is to investigate the combination of selumetinib and dexamethasone in the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL) in both adults and children. The trial is specifically for patients who have an identified change (mutation) in a particular gene in their cancer’s DNA. Phase I is to find the most suitable dose of selumetinib to safely give with dexamethasone. Phase II will use this dose to find out how well the combination works.

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible. 

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website (see the link below).

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More Information